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Selective serotonin reuptake inhibitors (SSRIs) are the most frequently used antidepressants during pregnancy.
There are conflicting results about their influence on pregnancy outcomes. The goal of this study was to update
our previous meta-analysis about pregnancy outcomes following exposure to SSRIs. For this purpose, all relevant
databases were searched from 1990 to March 2012 for studies investigating the pregnancy outcomes following
exposure to any therapeutic dosage of any SSRI (fluoxetine, paroxetine, citalopram, escitalopram, sertraline,
fluvoxamine) during pregnancy. Types of outcome investigated were spontaneous abortion, major malformations,
cardiovascular malformations, and minor malformations. A total of 25 studies met our criteria and were included in
the meta-analysis. The odds ratio (OD) values are 1.87 (95% CI: 1.5 to 2.33, P< 0.0001) for spontaneous abortion,
1.272 (95% CI: 1.098 to 1.474, P = 0.0014) for major malformations, 1.192 (95% CI: 0.39 to 3.644, P= 0.7578) for
cardiovascular malformations, and 1.36 (95% CI: 0.61 to 3.04, P= 0.4498) for minor malformations. The results
demonstrated that SSRIs increase the risk of spontaneous abortion and major malformations during pregnancy
while they don’t increase the risk of cardiovascular malformations and minor malformations. Our previous
meta-analysis only showed an increase in the risk of spontaneous abortion following the use of SSRIs during
pregnancy. This might be due to increase in the number of studies included or addition of two new SSRIs
(citalopram and escitalopram). The message to researchers is to try considering SSRIs individually during pregnancy
to reduce heterogeneity, although all are aware of inevitable limitations to study on pregnant mothers.
Keywords: Selective serotonin reuptake inhibitors (SSRIs), Pregnancy outcome, Meta-analysis, Evidence-based
medicine, Malformation, Systematic reviewIntroduction
Evidences show that there is an increase in psychiatric dis-
orders particularly depression and anxiety during pregnancy
[1,2]. Although the pathogenesis is unknown, hormonal
dysregulation, abnormalities in hypothalamic-pituitary-
adrenal axis activity, and the contributions of genetics and
epigenetics seems playing key roles in the development of* Correspondence: mohammad.abdollahi@utoronto.ca
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reproduction in any medium, provided the orperinatal mood disorders [3]. Women with depression dur-
ing pregnancy are at increased risk for premature delivery,
low birth weight, and postpartum depression [4,5].
The estimate is that up to 13% of all pregnant women
use an at least one antidepressant during pregnancy.
Selective serotonin reuptake inhibitors (SSRIs) are the
first-line, most frequently used antidepressants among
pregnant women [3]. However, some studies demon-
strated adverse pregnancy outcome following exposure to
SSRIs. Results from our recent meta-analysis published in
2006 revealed that SSRIs do not increase the risk of major
cardiovascular and minor malformations but do increasetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.darujps.com/content/20/1/75the risk of spontaneous abortion [6]. In the present study
we have updated our previous meta-analysis by including
more studies published in the recent 6 years about the
effects of SSRIs on pregnancy outcomes.
Methods
Data sources
Scopus, PubMed, Web of Science, and Cochrane Central
Register of Controlled Trials (CCRCT) were searched for
studies that investigated the effect of SSRIs on pregnancy
outcomes of depressive women. Data were collected for
the years 1990 to 2012 (up to March). The search terms
were “serotonin reuptake inhibitors” and “pregnancy”,
“birth outcome”, or “obstetrical outcome”. For PubMed,
all relevant MeSH terms were used. For Web of Science
and CCRCT, the same entry terms including their abbre-
viations were applied. The final queries were validated by
manual review and matching results. The reference lists
from retrieved articles were manually reviewed for finding
additional applicable studies.
Study selection
All controlled studies that investigated the effect of SSRIs
on pregnancy outcomes were considered. Spontaneous
abortion, major malformations, minor malformations, and
cardiovascular malformations were the key outcomes of
interest. Major malformations are all singular and com-
bined structural defects, syndromes, sequences, and asso-
ciations. Minor malformations include small structuralFigure 1 Flow diagram of the study selection process.developmental disturbances that do not impair viability
and do not need to be treated.
Studies and abstracts that were presented at meetings
were also considered. Two reviewers independently exam-
ined the title and abstract of each article to eliminate
duplicates, reviews, case studies, uncontrolled trials, trials
did not have desired outcomes, and trials published in lan-
guages other than English. Reviewers independently
extracted data on type of study, therapeutic regimens, time
of exposure, and outcome measures. Disagreements were
resolved by consensus.
Statistical analysis
Data from selected studies were extracted in the form of
2×2 Tables. Included studies were weighted and pooled.
The data were analyzed using StatsDirect software ver-
sion 2.7.8. Odds ratio (OR) and 95% confidence intervals
(95% CI) were calculated using the Mantel-Haenszel,
Robins-Breslow-Greenland and Der Simonian-Laird
methods. The Cochran Q test was used to test hetero-
geneity. In case of heterogeneity or probability of few
included studies in meta-analysis, the random effects for
individual and summary of effect size for weighted mean
difference was applied. Funnel plot analysis was used as
publication bias indicator.
Results
The electronic searches yielded 3192 items; 1143 from
PubMed, 67 from CCRCT, 655 from Web of Science, and
Table 1 Characteristics and results of studies included in meta-analysis
Study Drug Type Mean
maternal
age
Time of Ex Spontaneous abortion Major Mal Cardiovascular Mal Minor Mal










































Prospective cohort ND First trimester - - 19/506 25/928 - - - -
Diav-Citrin et al.
2008 [14]






Retrospective cohort 29.6 First trimester - - 75/2459 3369/107320 18/2459 512/107320 - -
Einarson et al.
2008 [16]












Retrospective ND Throughout - - 20/961 76/3861 - - 35/961 133/3861
Wogelius et al.
2006 [19]
ND, any SSRI Retrospective cohort ND First trimester - - 51/1051 5112/150780 - - - -
Vial et al.
2006 [20]









































32.9 First trimester - - 0/27 0/27 0/27 0/27 - -
Diav-Citrin et al.
2002 [25]



















31 First trimester 30/267 21/267 9/222 9/235 2/222 4/235 - -
Nulman et al.
1997 [29]
Fluoxetine Prospective cohort 30.5 First trimester - - 2/55 2/84 2/55 2/84 - -
Chambers et al.
1996 [30]
Fluoxetine Prospective cohort 31 First trimester 23/169 22/254 9/164 9/226 3/164 1/226 56/97 119/153
Pastuszak et al.
1993 [31]
Fluoxetine ND First trimester 19/128 10/128 9/28 2/110 1/98 0/110 - -
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http://www.darujps.com/content/20/1/751327 from Scopus. Of these, 52 trials were scrutinized in
full text and 25trials [7-31] were included in the analysis
(Figure 1). Type of study, SSRI subclass, and time of ex-
posure for each study are presented in Table 1.
Spontaneous abortion due to exposure to SSIRs in
comparison to placebo
The summary OR of spontaneous abortion for all
included data for SSRIs in comparison to placebo in
seven studies [20,21,25,27,28,30,31] was 1.87 with 95%
CI= 1.5 to 2.33 (P< 0.0001, Figure 2a). The Cochrane
Q test for heterogeneity indicated that the studies are
not heterogeneous (P= 0.3113, Figure 2b) and could be
combined, thus the fixed effects for individual and
summary for OR was applied. Regression of normal-
ized effect vs. precision for all included studies for
spontaneous abortion among SSRIs vs. placebo therapy
was 3.01 (95% CI= −6.94 to 0.924, P= 0.11) andOdds ratio meta-analysis plot [fixed effects]a
c
0.2 0.5 1 2 5 10
Diav-Citrin et al., 2002 1.86 (1.09, 3.13)
Einarson et al., 2001 1.51 (0.63, 3.73)
Kulin et al., 1998 1.48 (0.80, 2.81)
Chambers et al., 1996 1.66 (0.85, 3.25)
Pastuszak et al., 1993 2.06 (0.86, 5.17)
Vial et al., 2006 2.79 (1.79, 4.44)
Sivojelezova et al., 2005 1.04 (0.50, 2.29)
Combined [fixed] 1.87 (1.50, 2.33)
Odds ratio (95% confidence interval)
Bias assessment plot

















Figure 2 a. Individual and summary odds ratio for the outcome of “sp
pregnancy. b. Heterogeneity indicators for the outcome of “spontaneous
c. Publication bias indicators for the outcome of “spontaneous abortion” foKendall’s test on standardized effect vs. variance indi-
cated tau= −0.24, P= 0.38 (Figure 2c).
Major malformations post exposure to SSIRs in
comparison to placebo
The summary OR of major malformations for all
included data for SSRIs in comparison to placebo in
twenty one studies [7-9,11,13-15,18-31] was 1.272 with
95% CI = 1.098 to 1.474 (P = 0.0014, Figure 3a), a sig-
nificant results. The Cochrane Q test for heterogeneity
indicated that the studies are heterogeneous (P =
0.0198, Figure 3b) and could not be combined, thus the
random effects for individual and summary for OR was
applied. Regression of normalized effect vs. precision
for all included studies for major malformations among
SSRIs vs. placebo therapy was 0.75 (95% CI = −0.09 to
1.52, P = 0.08) and Kendall’s test on standardized effect
vs. variance indicated tau= 0.08, P = 0.66 (Figure 3c).L'Abbe plot (symbol size represents sample size)



















ontaneous abortion” for studies including SSRIs exposure during
abortion” for studies including SSRIs exposure during pregnancy.
r studies including SSRIs exposure during pregnancy.
Odds ratio meta-analysis plot [random effects]a
b
c
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L'Abbe plot (symbol size represents sample size)


































Figure 3 a. Individual and summary odds ratio for the outcome of “major malformations” for studies including SSRIs exposure
during pregnancy. b. Heterogeneity indicators for the outcome of “major malformations” for studies including SSRIs exposure during
pregnancy. c. Publication bias indicators for the outcome of “major malformations” for studies including SSRIs exposure during
pregnancy.
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http://www.darujps.com/content/20/1/75Cardiac malformations post exposure to SSIRs in
comparison to placebo
The summary OR of cardiac malformations for all
included data for SSRIs in comparison to placebo in 19
studies [7-12,14-17,20,23,24,26-31] was 1.192 with 95%
CI= 0.39 to 3.644 (Figure 4a). The Cochrane Q test for
heterogeneity indicated that the studies are heteroge-
neous (P< 0.0001, Figure 4b) and could not be com-
bined, thus the random effects for individual and
summary for OR was applied. Regression of normalized
effect vs. precision for all included studies for cardiac
malformations among SSRIs vs. placebo therapy was
2.18 (95% CI= −2.71 to 7.06, P= 0.36) and Kendall’s test
on standardized effect vs. variance indicated tau= −0.41,
P= 0.02 (Figure 4c).Minor malformations post exposure to SSIRs in
comparison to placebo
The summary OR of minor malformations for all
included data for SSRIs in comparison to placebo in
six studies [7,9,18,20,23,30] was 1.36 with 95%
CI= 0.61 to 3.04 (Figure 5a). The Cochrane Q test
for heterogeneity indicated that the studies are
heterogeneous (P< 0.0001, Figure 5b) and could not
be combined, thus the random effects for individual
and summary for OR was applied. Regression of nor-
malized effect vs. precision for all included studies
for minor malformations among SSRIs vs. placebo
therapy was −0.93 (95% CI= −9.38 to 7.52, P= 0.78)
and Kendall’s test on standardized effect vs. variance
indicated tau= −0.07, P= 0.72 (Figure 5c).
Odds ratio meta-analysis plot [random effects]a
b
c
0.001 0.01 0.10.20.51 2 5 10 100 1000
Kornum et al., 2010 1.932 (1.255, 2.852)
Colvin et al., 2011 1.596 (1.066, 2.305)
Mal et al., 2011 1.279 (1.054, 1.538)
Nordeng et al., 2012 1.486 (0.675, 3.275)
Casper et al., 2003 3.240 (0.190, infinity)
Costei et al., 2002 1.000 (0.000, 39.000)
Simon et aL., 2002 0.497 (0.008, 9.647)
Einarson et al., 2001 1.106 (0.014, 87.423)
Kulin et al., 1998 0.525 (0.047, 3.710)
Nulman et al., 1997 1.547 (0.109, 21.874)
Chambers et al., 1996 4.193 (0.332, 221.054)
Pastuszak et al., 1993 3.400 (0.211, infinity)
Vial et al., 2006 1.180 (0.157, 8.849)
Kallen and OtterbladOlausson, 2007 0.032 (0.025, 0.040)
Oberlander et al., 2008 1.538 (0.903, 2.461)
Wichman et al., 2009 0.440 (0.090, 1.309)
Diav-Citrin et al., 2008 4.028 (1.566, 11.135)
Kornum et al., 2010 1.932 (1.255, 2.852)
Merlob et al., 2009 2.166 (0.921, 4.356)
Combined [random] 1.192 (0.390, 3.644)
Odds ratio (95% confidence interval)
Bias assessment plot
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Figure 4 a. Individual and summary odds ratio for the outcome of “cardiac malformations” for studies including SSRIs exposure during
pregnancy. b. Heterogeneity indicators for the outcome of “cardiac malformations” for studies including SSRIs exposure during pregnancy.
c. Publication bias indicators for the outcome of “cardiac malformations” for studies including SSRIs exposure during pregnancy.
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The present study was done to update our previous
meta-analysis on the effects of exposure to SSRIs during
pregnancy on four obstetrical outcomes including major
malformations, cardiovascular malformations, minor
malformations, and spontaneous abortion, to evaluate
whether SSRIs increase the risk of these outcomes. The
results showed that SSRIs increase the risk of spontan-
eous abortion and major malformations significantly but
the risk of minor and cardiovascular malformations did
not show significant increase. Our previous meta-
analysis demonstrated only a significant increase in the
risk of spontaneous abortion while in the current study
the risk of major malformations was increased by SSRIs.
There are some differences between current meta-
analysis and previous one. One is the number of studies
included because collection of data for previous meta-
analysis was up to August 2005 but for the current onewas up to March 2012. In the previous meta-analysis,
only 9 studies were eligible to be included while there
were 25 eligible studies in the present meta-analysis.
Thus the number of subjects included for each outcome
is dramatically increased in the current meta-analysis. In
previous meta-analysis, 2378 subjects included for spon-
taneous abortion whereas 4140 subjects included for this
outcome in the current one; 2699 subjects for major
malformations in the previous vs.1135131 in the current
one; 1923 for cardiac malformation in previous vs.
1476987 in the current one; and 883 for minor malfor-
mations in the previous vs.698770 in the current one.
Therefore, although the results for outcomes of spontan-
eous abortion, minor malformations and cardiac malfor-
mations are not apparently different from previous
meta-analysis, the current results are more accurate and
reliable. Interestingly, the number of major malforma-
tions in the current meta-analysis is significant while it
Odds ratio meta-analysis plot [random effects]a
c
0.01 0.1 0.2 0.5 1 2 5 10 100
Colvin et al., 2011 3.65 (2.44, 5.26)
Nordeng et al., 2012 1.37 (0.79, 2.36)
Casper et al., 2003 2.94 (0.59, 14.28)
Chambers et al., 1996 0.39 (0.22, 0.71)
Vial et al., 2006 1.18 (0.02, 92.75)
Wen et al., 2006 1.06 (0.70, 1.56)
Combined [random] 1.36 (0.61, 3.04)
Odds ratio (95% confidence interval)
L'Abbe plot (symbol size represents sample size)

































Figure 5 a. Individual and summary odds ratio for the outcome of “minor malformations” for studies including SSRIs exposure during
pregnancy. b. Heterogeneity indicators for the outcome of “minor malformations” for studies including SSRIs exposure during pregnancy. c.
Publication bias indicators for the outcome of “minor malformations” for studies including SSRIs exposure during pregnancy.
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http://www.darujps.com/content/20/1/75was non-significant in the previous one. One explan-
ation for this difference is the number of included sub-
jects that is about 800-times higher than that of previous
one. Though the risk of major malformations was statis-
tically non-significant but it was clinically significant in
previous meta-analysis. The addition of two new drugs
to the list of SSRIs from the year 2008 named citalopram
and escitalopram is a good reason to this new finding.
Use of citalopram during pregnancy was associated with
neural tube defects [8] and septal heart defects [32]. To
obtain more convincing results, it is suggested to evalu-
ate pregnancy outcomes after exposure to individual
SSRIs not all SSRIs together especially for citalopram
and escitalopram. However, there are two meta-analyses
about the effect of paroxetine in congenital malforma-
tions [33]. The results of these studies have shown an
increased prevalence of congenital defects and heart
defects with first trimester paroxetine use.Overall, this study demonstrates an increase risk of
major malformation and spontaneous abortion following
the use of SSRIs during pregnancy. This study does not
show an increased risk for heart defects and minor mal-
formations. Again we would like to emphasize to con-
sider evaluation of SSRIs in pregnancy individually.
This advice is because of different reports about con-
genital malformations for any of them. For example,
increased risk of neural defects for citalopram [8] or
increased prevalence of heart defects after use of par-
oxetine during pregnancy [34] can be emphasized. Of
course it should not be forgotten that clinical study
in pregnancy and pregnant mothers has its own lim-
itations and that is why in most of meta-analysis
studies, problem of data aggregation among included
studies exists [6,35-38] but they are inevitable limita-
tions of such studies and therefore conducted meta-
analyses.
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